Amarin Corp. PLC ADR (AMRN): Price and Financial Metrics

Amarin Corp. PLC ADR (AMRN): $1.54

0.01 (+0.65%)

POWR Rating

Component Grades













Add AMRN to Watchlist
Sign Up

Industry: Biotech



in industry


  • AMRN scores best on the Value dimension, with a Value rank ahead of 80.58% of US stocks.
  • AMRN's strongest trending metric is Momentum; it's been moving up over the last 177 days.
  • AMRN ranks lowest in Stability; there it ranks in the 8th percentile.

AMRN Stock Summary

  • The ratio of debt to operating expenses for AMARIN CORP PLC is higher than it is for about just 7.7% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, AMARIN CORP PLC is reporting a growth rate of -1,008.84%; that's higher than merely 1.85% of US stocks.
  • Revenue growth over the past 12 months for AMARIN CORP PLC comes in at -36.69%, a number that bests merely 5.69% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to AMARIN CORP PLC, a group of peers worth examining would be POWL, CLIR, CDXC, IRMD, and ISDR.
  • AMRN's SEC filings can be seen here. And to visit AMARIN CORP PLC's official web site, go to

AMRN Valuation Summary

  • In comparison to the median Healthcare stock, AMRN's EV/EBIT ratio is 160.61% lower, now standing at -4.
  • AMRN's price/sales ratio has moved NA NA over the prior 149 months.

Below are key valuation metrics over time for AMRN.

Stock Date P/S P/B P/E EV/EBIT
AMRN 2023-03-24 1.7 1.0 -5.9 -4.0
AMRN 2023-03-23 1.7 1.0 -5.8 -3.9
AMRN 2023-03-22 1.7 1.0 -5.9 -4.0
AMRN 2023-03-21 1.8 1.1 -6.2 -4.3
AMRN 2023-03-20 1.7 1.1 -6.0 -4.1
AMRN 2023-03-17 1.7 1.1 -5.9 -4.0

AMRN Growth Metrics

    Its year over year net income to common stockholders growth rate is now at -2495.69%.
  • Its 3 year net cashflow from operations growth rate is now at -19.26%.
  • Its 4 year net income to common stockholders growth rate is now at 75.79%.
Over the past 67 months, AMRN's revenue has gone up $284,261,000.

The table below shows AMRN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 423.439 -209.884 -91.961
2022-06-30 475.599 -196.211 -99.972
2022-03-31 535.647 -146.68 -22.208
2021-12-31 583.187 -66.537 7.729
2021-09-30 605.947 -76.62 -2.043
2021-06-30 620.408 -61.227 4.32

AMRN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AMRN has a Quality Grade of B, ranking ahead of 81.41% of graded US stocks.
  • AMRN's asset turnover comes in at 0.626 -- ranking 51st of 680 Pharmaceutical Products stocks.
  • CEMI, NEOG, and INSM are the stocks whose asset turnover ratios are most correlated with AMRN.

The table below shows AMRN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.626 0.793 0.031
2021-03-31 0.628 0.792 0.019
2020-12-31 0.652 0.786 -0.036
2020-09-30 0.641 0.784 -0.042
2020-06-30 0.608 0.781 -0.052
2020-03-31 0.668 0.778 -0.163

AMRN Stock Price Chart Interactive Chart >

Price chart for AMRN

AMRN Price/Volume Stats

Current price $1.54 52-week high $3.74
Prev. close $1.53 52-week low $1.04
Day low $1.52 Volume 1,482,900
Day high $1.56 Avg. volume 4,709,240
50-day MA $1.79 Dividend yield N/A
200-day MA $1.45 Market Cap 621.90M

Amarin Corp. PLC ADR (AMRN) Company Bio

Amarin Corporation plc, a biopharmaceutical company, focuses on developing and commercializing therapeutics for the treatment of cardiovascular diseases in the United States. The company was founded in 1989 and is based in Dublin, Ireland.

AMRN Latest News Stream

Event/Time News Detail
Loading, please wait...

AMRN Latest Social Stream

Loading social stream, please wait...

View Full AMRN Social Stream

Latest AMRN News From Around the Web

Below are the latest news stories about AMARIN CORP PLC that investors may wish to consider to help them evaluate AMRN as an investment opportunity.

Reconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA® (Icosapent Ethyl)

New Amarin Board Believes the Company Will Thrive with Proper Stewardship New Amarin Directors are Working with Urgency to Address Issues at Amarin DUBLIN, Ireland and BRIDGEWATER, N.J., March 16, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today released the following statement: Since joining the company two weeks ago, the new Amarin board has rolled up its sleeves and begun the hard work of creating value for shareholders. We continue to believe that Amarin has tremendous po

Yahoo | March 16, 2023

Amarin Announces Board Departures

DUBLIN, Ireland and BRIDGEWATER. N.J., March 06, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the “Company”) today announced that, in the interest of the Company to avoid further proxy contests, all seven independent non-Sarissa board members: Adam Berger, Erin Enright, Geraldine Murphy, Kristine Peterson, Dr. Murray Stewart, Jan van Heek and Alfonso “Chito” Zulueta will resign from the Board of Directors, effective immediately. The departing members of the Amarin

Yahoo | March 6, 2023

Amarin Posts New Data Showing Benefit of Vascepa In High-Risk Patients With Acute Coronary Syndrome

Amarin Corporation plc (NASDAQ: AMRN) announced a new analysis from the Vascepa/Vazkepa (icosapent ethyl) cardiovascular outcomes REDUCE-IT study. The study exhibited the effectiveness of Vascepa/Vazkepa in patients with the recent acute coronary syndrome. The post-hoc analysis showed that icosapent ethyl (IPE) substantially and significantly reduced the risk of first and total ischemic events by 37% and 36%, respectively, in patients with the recent acute coronary syndrome (ACS) without increas

Yahoo | March 6, 2023

Amarin Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23/WCC

--In Vitro Data Presentations Support Antithrombotic and Antioxidant Effects of EPA Compared with DHA, No Impact of Mineral Oil on Rates of LDL Oxidation -– DUBLIN, Ireland and BRIDGEWATER, N.J., March 06, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted new in vitro data supporting the potential mechanistic effects of eicosapentaenoic acid (EPA) in reducing cardiovascular events in at-risk patients presented at the joint ACC.23 together with the World Congress of

Yahoo | March 6, 2023

Amarin Announces New REDUCE-IT® Data at ACC.23/WCC Showing Benefit of VASCEPA®/VAZKEPA® (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event

--Post-Hoc Analysis Shows IPE Significantly Reduced Risk of First, Total Ischemic Events by 37% and 36% Respectively in Patients with Recent ACS Without Increased Bleeding-- --Analysis Builds on Consistently Demonstrated Positive Outcomes for VASCEPA/VAZKEPA Across Sub-Populations in REDUCE-IT, Including in Patients with Prior Myocardial Infarction (MI), Prior Revascularization, Prior Peripheral Arterial Disease (PAD) and Diabetes-- DUBLIN, Ireland and BRIDGEWATER, N.J., March 05, 2023 (GLOBE NE

Yahoo | March 5, 2023

Read More 'AMRN' Stories Here

AMRN Price Returns

1-mo -24.14%
3-mo 27.27%
6-mo 41.28%
1-year -52.76%
3-year -88.66%
5-year -48.84%
YTD 27.27%
2022 -64.09%
2021 -31.08%
2020 -77.19%
2019 57.53%
2018 239.40%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8166 seconds.